| Synonyms: | |
| Status: | Phase 1 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | FB7ZTJ8M8A |
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C28H29ClN2O3S |
| Molecular Weight | 509.07 |
| AlogP | 6.15 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 6.0 |
| Polar Surface Area | 72.19 |
| Molecular species | None |
| Aromatic Rings | 4.0 |
| Heavy Atoms | 35.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| AGONIST | LXR-beta agonist |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Hydrolase
|
- | - | - | - | ||
|
Enzyme
|
- | - | - | - | ||
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 1
Nuclear hormone receptor subfamily 1 group H
Nuclear hormone receptor subfamily 1 group H member 3
|
33-1200 | - | - | 14-14 | - | |
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 2
Nuclear hormone receptor subfamily 2 group B
Nuclear hormone receptor subfamily 2 group B member 1
|
- | - | - | 14-14 | - |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Atherosclerosis | 1 | D050197 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL3545418 |
| FDA SRS | FB7ZTJ8M8A |
CONTENTS